Standard of Care - Double Oral — Competitive Intelligence Brief

Standard of Care - Double Oral (Standard of Care - Double Oral) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antithrombotic combination therapy. Area: Cardiovascular.

marketed Antithrombotic combination therapy Cardiovascular Small molecule

Target snapshot

Standard of Care - Double Oral (Standard of Care - Double Oral) — AOP Orphan Pharmaceuticals AG. This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard of Care - Double Oral TARGET	Standard of Care - Double Oral	AOP Orphan Pharmaceuticals AG	marketed	Antithrombotic combination therapy
Triple antithrombotic therapy	Triple antithrombotic therapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Antithrombotic combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antithrombotic combination therapy class)

1. AOP Orphan Pharmaceuticals AG · 1 drug in this class
2. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class